Live feed21:00:00·33mPRReleasevia QuantisnowAbbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLCByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
